Orziloben

N/A

Report date: 2024/12/26 14:59:45
NME

Base Information

Drug NameOrziloben
Drug Alias Namemedium chain fatty acid (MCFA) analogueNST-6179SEFA-6179
ClassificationSmall molecules
Mechanisms of ActionFatty acid replacements
TargetsNot applicable
Therapy Area/IndicationsLiver DiseasesShort Bowel Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPronova Biopharma Norge As
China Registration ClassN/A

Develop Information

Active CompaniesNorthsea Therapeutics Bv
Inactive CompaniesN/A
Active IndicationsLiver DiseasesShort Bowel Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A